RecruitingPhase 1NCT04192344

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Sponsor

Abbisko Therapeutics Co, Ltd

Enrollment

276 participants

Start Date

Jan 20, 2020

Study Type

INTERVENTIONAL

Conditions

Neoplasms Tenosynovial Giant Cell Tumor

Summary

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ABSK021 for people with neoplasms and tenosynovial giant cell tumor. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGABSK021

ABSK021 oral capsule

Locations(17)

Precision NextGen Oncology

Beverly Hills, California, United States

SCRI at HealthOne

Denver, Colorado, United States

The Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

MD Anderson Cancer Center

Houston, Texas, United States

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Sun Yat-sen University

Guangdong, Guangzhou, China

Hebei Medical University Third Hospital

Shijiazhuang, Hebei, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou Universtity

Zhengzhou, Henan, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

Liaoning Cancer Hospital

Shenyang, Liaoning, China

Huashan Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Shanghai Sixth People's Hospital

Shanghai, Shanghai Municipality, China

Xi'an Hong Hui Hospital

Xian, Shanxi, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04192344

Related Trials

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796209 locations

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT033661161 location

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT0721360922 locations

Collection of Tissue Samples for Cancer Research

NCT0090019817 locations

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NCT014434682 locations